Hematopoietic growth factors. Defining the appropriate clinical role in multimodality cancer therapy.

No abstract is available for this paper.

• Publication year

  1995

• Venue

  Chest

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 7540124
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.

  1994cited by this paper
• Incidence of neutropenic fever in patients treated with standard-dose combination chemotherapy for small-cell lung cancer and the cost impact of treatment with granulocyte colony-stimulating factor.

  1994cited by this paper
• Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy.

  1993cited by this paper
• Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial.

  1992cited by this paper
• Hematopoietic growth factors: current knowledge, future prospects.

  1992cited by this paper
• Granulocyte-macrophage colony-stimulating factor (GM-CSF): preclinical and clinical investigations.

  1992cited by this paper
• Severe myelosuppression resulting from concurrent administration of granulocyte colony-stimulating factor and cytotoxic chemotherapy.

  1992cited by this paper
• Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (1).

  1992cited by this paper
• Use of recombinant human erythropoietin in the treatment of anemia in patients who have cancer.

  1992cited by this paper
• Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (2).

  1992cited by this paper
• Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer.

  1991cited by this paper
• Granulocyte colony-stimulating factor and its receptor.

  1991cited by this paper
• Dose-response in the treatment of breast cancer: a critical review.

  1988cited by this paper
• The molecular control of blood cell development.

  1987cited by this paper
• Granulocyte-macrophage colony-stimulating factors

  1985cited by this paper
• Dose: a critical factor in cancer chemotherapy.

  1980cited by this paper
• Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia.

  1966cited by this paper
• Acute leukemia.

  1966cited by this paper

• Cell-derived Bone marrow-mimetics induce erythroid lineage commitment of hematopoietic stem and progenitor cells ex-vivo

  2017cites this paper
• Response patterns of cytokines/chemokines in two murine strains after irradiation.

  2012cites this paper
• Lung Cancer

  2006cites this paper
• Aerosol granulocyte macrophage-colony stimulating factor: a low toxicity, lung-specific biological therapy in patients with lung metastases.

  1999cites this paper
• Comparison of Cytokines in Children with Recurrent Solid Tumors Treated with Intensive Chemotherapy

  1998cites this paper
• Lung cancer.

  1997cites this paper
• Macromolecular versus small-molecule therapeutics: drug discovery, development and clinical considerations.

  1996cites this paper